Femasys Inc. (NASDAQ:FEMY) Short Interest Up 106.2% in February

Femasys Inc. (NASDAQ:FEMY) was the target of a large growth in short interest in the month of February. As of February 15th, there was short interest totalling 298,300 shares, a growth of 106.2% from the January 31st total of 144,700 shares. Approximately 1.4% of the shares of the company are short sold. Based on an average daily volume of 275,300 shares, the days-to-cover ratio is presently 1.1 days.

Analysts Set New Price Targets

A number of research analysts have issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $12.00 price target on shares of Femasys in a research report on Wednesday. Chardan Capital reduced their price target on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a research report on Wednesday, November 13th.

Femasys Stock Down 1.3 %

NASDAQ FEMY traded down $0.02 during trading on Friday, hitting $1.57. 145,280 shares of the company traded hands, compared to its average volume of 273,881. The company has a market capitalization of $35.95 million, a P/E ratio of -1.94 and a beta of -2.81. The business has a fifty day simple moving average of $1.24 and a 200 day simple moving average of $1.17. Femasys has a 12 month low of $0.86 and a 12 month high of $2.40. The company has a current ratio of 3.94, a quick ratio of 3.26 and a debt-to-equity ratio of 0.86.

Institutional Investors Weigh In On Femasys

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC bought a new stake in shares of Femasys during the 4th quarter worth $25,000. Aljian Capital Management LLC bought a new position in shares of Femasys in the third quarter worth about $27,000. Jane Street Group LLC acquired a new position in shares of Femasys during the 4th quarter worth about $30,000. XTX Topco Ltd lifted its position in shares of Femasys by 123.9% during the 3rd quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after purchasing an additional 18,004 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in shares of Femasys during the 4th quarter worth about $45,000. 65.27% of the stock is currently owned by institutional investors and hedge funds.

Femasys Company Profile

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.